Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid
deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia …

Nonalcoholic fatty liver disease (NAFLD) is a worldwide rising challenge because of hepatic,
but also extrahepatic, complications. Thyroid hormones are master regulators of energy and …

Non-alcoholic fatty liver disease (NAFLD) causes significant global disease burden and is a
leading cause of mortality. NAFLD induces a myriad of aberrant changes in hepatocytes at …

Introduction Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic
liver disease worldwide and closely interconnected to the metabolic syndrome. Liver …

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pose a
significant threat to human health and cause a tremendous socioeconomic burden …

Nonalcoholic fatty liver disease (NAFLD, including nonalcoholic fatty liver (NAFL) and
nonalcoholic steatohepatitis (NASH)) is a high-prevalence disorder, affecting about 1 billion …

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly termed
nonalcoholic fatty liver disease (NAFLD), is a widespread global health concern that affects …

The prevalence of hypothyroidism in patients with nonalcoholic fatty liver disease (NAFLD)
is high (22.4%). Thyroid hormones (THs) regulate many metabolic activities in the liver by …

Thyroid hormones (triiodothyronine and thyroxine) are pivotal for metabolic balance in the
liver and entire body. Dysregulation of the hypothalamus–pituitary–thyroid axis can …

Thyroid hormones (THs) and TH receptor-beta (TRβ) reduce hepatic triglycerides, indicating
a therapeutic potential for TH analogs in liver steatosis. To avoid adverse extrahepatic …